NO20020774L - Farmasöytisk middel omfattende et benzamid-derivat som aktiv forbindelse - Google Patents

Farmasöytisk middel omfattende et benzamid-derivat som aktiv forbindelse

Info

Publication number
NO20020774L
NO20020774L NO20020774A NO20020774A NO20020774L NO 20020774 L NO20020774 L NO 20020774L NO 20020774 A NO20020774 A NO 20020774A NO 20020774 A NO20020774 A NO 20020774A NO 20020774 L NO20020774 L NO 20020774L
Authority
NO
Norway
Prior art keywords
active compound
pharmaceutical agent
benzamide derivative
benzamide
derivative
Prior art date
Application number
NO20020774A
Other languages
English (en)
Other versions
NO20020774D0 (no
NO328957B1 (no
Inventor
Tsuneji Suzuki
Tomoyuki Ando
Masahiko Ishibashi
Masahiro Sakabe
Ikuo Sakai
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20020774D0 publication Critical patent/NO20020774D0/no
Publication of NO20020774L publication Critical patent/NO20020774L/no
Publication of NO328957B1 publication Critical patent/NO328957B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20020774A 1999-08-16 2002-02-15 Farmasoytisk middel omfattende et benzamid-derivat som aktiv forbindelse NO328957B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22955199A JP2001064177A (ja) 1999-08-16 1999-08-16 ベンズアミド誘導体を有効成分とする製剤
PCT/EP2000/008011 WO2001012193A1 (en) 1999-08-16 2000-08-16 Pharmaceutical agent comprising a benzamide derivative as active ingredient

Publications (3)

Publication Number Publication Date
NO20020774D0 NO20020774D0 (no) 2002-02-15
NO20020774L true NO20020774L (no) 2002-03-04
NO328957B1 NO328957B1 (no) 2010-06-28

Family

ID=16893948

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020774A NO328957B1 (no) 1999-08-16 2002-02-15 Farmasoytisk middel omfattende et benzamid-derivat som aktiv forbindelse

Country Status (29)

Country Link
EP (1) EP1207881B1 (no)
JP (2) JP2001064177A (no)
KR (1) KR100683876B1 (no)
CN (1) CN1205931C (no)
AR (1) AR031074A1 (no)
AU (1) AU780151B2 (no)
BG (1) BG65662B1 (no)
BR (1) BR0013283A (no)
CA (1) CA2380757C (no)
CY (1) CY1116273T1 (no)
CZ (1) CZ302924B6 (no)
DK (1) DK1207881T3 (no)
EE (1) EE05331B1 (no)
ES (1) ES2536705T3 (no)
HK (1) HK1046501B (no)
HR (1) HRP20020181B1 (no)
HU (1) HU230386B1 (no)
IL (1) IL148169A0 (no)
MX (1) MXPA02001575A (no)
NO (1) NO328957B1 (no)
NZ (1) NZ517356A (no)
PL (1) PL201388B1 (no)
PT (1) PT1207881E (no)
RU (1) RU2257206C2 (no)
SK (1) SK287547B6 (no)
TW (1) TWI245630B (no)
UA (1) UA73316C2 (no)
WO (1) WO2001012193A1 (no)
ZA (1) ZA200201466B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001081031A (ja) * 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
CA2423329A1 (en) * 2000-09-22 2003-03-20 Takeda Chemical Industries, Ltd. Solid preparations
WO2003075856A2 (en) 2002-03-07 2003-09-18 University Of Delaware Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea
GB0316206D0 (en) 2003-07-10 2003-08-13 Glaxo Group Ltd Pharmaceutical formulation
WO2008123395A1 (ja) 2007-03-28 2008-10-16 Santen Pharmaceutical Co., Ltd. ヒストン脱アセチル化酵素阻害作用を有する化合物を有効成分として含有する眼圧下降剤
KR101405615B1 (ko) * 2007-08-27 2014-06-12 (주)아모레퍼시픽 조성물 내 ｐＨ 조절을 통해 안정화된 벤즈아미드 화합물을함유하는 피부 외용제 조성물, 및 그 벤즈아미드 화합물안정화 방법
PT2350005E (pt) * 2008-08-29 2012-03-12 Bayer Pharma AG Polimorfo b de n-(2-aminofenil)-4-[n-(piridina-3-il)¿ metoxicarbonil-aminometil]-benzamida (ms-275)
GB2462893B (en) * 2008-08-29 2010-10-13 Bayer Schering Pharma Ag N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
CN104334169B (zh) * 2013-04-04 2016-11-02 第一三共株式会社 包含氨基羧酸盐的固体组合物
US10561628B2 (en) 2015-03-19 2020-02-18 Daiichi Sankyo Company, Limited Solid preparation including antioxidant
BR112017019920B1 (pt) 2015-03-19 2023-11-07 Daiichi Sankyo Company, Limited Preparação sólida farmacêutica, e, método para estabilização de uma preparação sólida farmacêutica
TWI845532B (zh) 2018-07-30 2024-06-21 日商第一三共股份有限公司 含安定劑之醫藥品的固體製劑
CN111867559A (zh) * 2019-01-25 2020-10-30 株式会社爱茉莉太平洋 含有苯甲酰胺化合物以及增溶剂的组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer

Also Published As

Publication number Publication date
BG106516A (en) 2002-10-31
PT1207881E (pt) 2015-06-05
CY1116273T1 (el) 2017-02-08
NO20020774D0 (no) 2002-02-15
CZ302924B6 (cs) 2012-01-18
PL353449A1 (en) 2003-11-17
DK1207881T3 (da) 2015-06-22
IL148169A0 (en) 2002-09-12
AU6442700A (en) 2001-03-13
HUP0203226A3 (en) 2003-12-29
CN1205931C (zh) 2005-06-15
BR0013283A (pt) 2002-04-23
AU780151B2 (en) 2005-03-03
TWI245630B (en) 2005-12-21
WO2001012193A1 (en) 2001-02-22
BG65662B1 (bg) 2009-05-29
NZ517356A (en) 2003-07-25
ZA200201466B (en) 2002-09-02
KR100683876B1 (ko) 2007-02-15
JP2001064177A (ja) 2001-03-13
CA2380757A1 (en) 2001-02-22
JP4854158B2 (ja) 2012-01-18
MXPA02001575A (es) 2003-10-14
EE200200073A (et) 2003-04-15
AR031074A1 (es) 2003-09-10
HK1046501B (zh) 2005-09-30
RU2002106815A (ru) 2004-01-27
KR20020020815A (ko) 2002-03-15
ES2536705T3 (es) 2015-05-27
SK2092002A3 (en) 2002-07-02
EP1207881B1 (en) 2015-04-01
EP1207881A1 (en) 2002-05-29
CN1370068A (zh) 2002-09-18
HRP20020181B1 (hr) 2016-01-29
CZ2002540A3 (cs) 2002-06-12
HRP20020181A2 (en) 2005-10-31
SK287547B6 (sk) 2011-01-04
HK1046501A1 (en) 2003-01-17
RU2257206C2 (ru) 2005-07-27
HUP0203226A2 (hu) 2003-01-28
UA73316C2 (uk) 2005-07-15
HU230386B1 (hu) 2016-03-29
PL201388B1 (pl) 2009-04-30
CA2380757C (en) 2009-01-27
NO328957B1 (no) 2010-06-28
JP2003507330A (ja) 2003-02-25
EE05331B1 (et) 2010-08-16

Similar Documents

Publication Publication Date Title
EE05063B1 (et) Bensamiididerivaati sisaldav farmatseutiline preparaat
NO20002173L (no) Pleuromutilin-derivater som antimikrobielle midler
DK1207868T3 (da) Farmaceutiske tramadolsalte
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
PT1220856E (pt) Compostos farmaceuticamente activos
NO20042807L (no) Farmasoytiske sammensetninger som innbefatter aktive vitamin D forbindelser
NO20043702L (no) 8-azaprostaglandinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
NO20014412L (no) Forbindelser nyttige som anti-inflammatoriske midler
DK1218374T3 (da) Farmaceutisk aktive sulfonamidderivater
NO20015664L (no) Nye farmasöytisk aktive forbindelser
DK1498411T3 (da) Diketohydrazinderivatforbindelser og medikamenter indeholdende forbindelserne som den aktive bestanddel
NO20020774L (no) Farmasöytisk middel omfattende et benzamid-derivat som aktiv forbindelse
NO20025635L (no) Anvendelse av biguanidderivater til fremstilling av et legemiddel som har en sarhelende virkning
DK1268419T3 (da) Farmaceutisk aktive pyrrolidinderivater som BAX-inhibitorer
ATE455754T1 (de) Arylsulfonamid-substituierte hydroxamsäure- derivate
NO20013675L (no) 2,3,4,5-tetrahydro-1H-[1,4)benzodiazepin-3-hydroksamsyre som matriks-metalloproteinase-inhibitorer
NO20030100L (no) Pleuromutilinderivater som har antibakteriell aktivitet
FR2852845B1 (fr) Compositions pharmaceutiques a activite antibiotique
DK1231211T3 (da) Thiazolidindion-derivater som antidiabetika
NO980923D0 (no) Optisk aktivt fenylpyrimidin-derivat som analgetisk middel
NO20012965D0 (no) Sulfonyloksazolaminer som terapeutisk aktive forbindelser
NO20030474L (no) Legemiddel mot demens inneholdende 2-aryl-8- oksodihydropurinderivater som aktiv bestanddel
FR2800028B1 (fr) Actionneur a piston actif
NO20032035D0 (no) Terapeutiske midler for heratokonjunktivitis sykdommer omfattende farnesyleddiksyre som aktiv ingrediens
NO20020044D0 (no) Terapeutisk middel for legemiddel-resistent hypercalcemi

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

MK1K Patent expired